Table 2.
Gene sets dysregulated in liver of obese or obese diabetic subjects compared to lean subjects or correlated with clinical phenotypes using GSEA
| Size | ES | NES | Nominal P value | FDR Q value | |
|---|---|---|---|---|---|
| Gene sets enriched with altered genes in study groups | |||||
| Downregulated in obese subjects | |||||
| Regulated_Thyroidhormone_Muscle | 365 | 0.43 | 1.86 | <0.001 | 0.071 |
| mRNA processing | 107 | 0.43 | 1.87 | <0.001 | 0.142 |
| Melton_Stemness | 254 | 0.41 | 1.79 | <0.001 | 0.185 |
| Leptin pathway | 23 | 0.60 | 1.73 | <0.001 | 0.217 |
| Histidine metabolism | 34 | 0.51 | 1.74 | 0.030 | 0.239 |
| Upregulated in obese diabetic subjects | |||||
| Glycolysis pathway | 30 | 0.72 | 1.97 | 0.042 | 0.170 |
| Enriched with genes correlation with clinical phenotypes | |||||
| Positive correlation with HOMA-IR | |||||
| T_ALL_Downing_ALL | 116 | 0.58 | 2.23 | <0.001 | <0.001 |
| Eosinophils pathway | 19 | 0.72 | 1.95 | <0.001 | 0.065 |
Gene sets with FDR <0.25 are shown. No gene sets were enriched (FDR Q <0.25) for upregulation in obese subjects or downregulation in obese diabetic subjects, or for the correlation with liver fat content, fasting glucose, fasting insulin, or HbA1c. ES, Enrichment score; NES, normalized enrichment score.